Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million on February 26, 2024. As for consideration, purchase price comprises, $8 million upfront, which is payable at closing in the form of $2 million and $6 million in ordinary shares, equating to approximately 0.82 million ordinary shares, $5 million performance-related milestone payments, payable in cash, that are subject to meeting milestone conditions within twelve months of closing, and a two-year revenue share based on actual revenue earned from existing customers of IsoTherapeutics total estimated cash payments $0.6 million. Transaction is subject to Closing of the customary conditions, including regulatory approvals.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.39 AUD | +0.13% | +2.33% | +52.68% |
05:34am | Telix Pharmaceuticals Concludes Proof-of-Concept Study of Advanced Prostate Cancer Drug | MT |
May. 20 | Telix Pharmaceuticals Files Registration Statement for Nasdaq IPO | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.68% | 3.43B | |
+40.34% | 54.04B | |
+45.55% | 41.96B | |
-1.71% | 41.92B | |
-7.20% | 28.35B | |
+12.40% | 26.35B | |
-21.34% | 19B | |
+6.42% | 13B | |
+28.53% | 12.28B | |
+25.59% | 12.19B |
- Stock Market
- Equities
- TLX Stock
- News Telix Pharmaceuticals Limited
- Telix Pharmaceuticals Limited entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million.